Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
The new Zigly center features and offers comprehensive veterinary services
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
A triple-action Formula for comprehensive respiratory relief
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
Over 100 million cartridges of rh-insulin supplied to Malaysian health ministry; 345,000+ patients served
Extended lab space for product development, customer demos, and training
The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
